GSK to cut 12% of US sales force

10 November 2008

UK drug major GlaxoSmithKline is to cut 12% of its US sales force as part of a scheme to save L700.0 million ($1.11 billion) a year by 2010, according to media reports. The UK firm is to eliminate 1,800 positions, some of which are vacant, moving some staff to its vaccines unit, for total lay-offs of around 1,000 employees. GSK will also re-organize its remaining workforce by treatment area, rather than by geographic region as before, in a bid to win over health care professionals.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight